Synthesis of 7-deaza-8-bromo cyclic adenosine 5'-diphosphate ribose: The first hydrolysis resistant antagonist at the cADPR receptor

被引：15

作者：

Bailey, VC

Sethi, JK

Galione, A

Potter, BVL

机构：

[1] UNIV BATH,SCH PHARM & PHARMACOL,DEPT MED CHEM,BATH BA2 7AY,AVON,ENGLAND

[2] UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND

来源：

CHEMICAL COMMUNICATIONS | 1997年 / 07期

关键词：

D O I：

10.1039/a700336f

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

7-Deaza-8-bromo cyclic adenosine 5'-diphosphate ribose is synthesised from 7-deazaadenosine via 7-deaza-8-bromo nicotinamide adenine dinucleotide; it is both a more potent antagonist than the 8-bromo derivative and has the advantage of chemical and enzymatic hydrolytic stability.

引用

页码：695 / 696

页数：2

共 22 条

[1] ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1929
[2] CHEMOENZYMATIC SYNTHESIS OF ANALOGS OF THE 2ND-MESSENGER CANDIDATE CYCLIC ADENOSINE 5'-DIPHOSPHATE RIBOSE
ASHAMU, GA
GALIONE, A
POTTER, BVL
[J]. JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1995, (13) : 1359 - 1360
[3] 7-Deaza cyclic adenosine 5'-diphosphate ribose: First example of a Ca2+-mobilizing partial agonist related to cyclic adenosine 5'-diphosphate ribose
Bailey, VC
Sethi, JK
Fortt, SM
Galione, A
Potter, BVL
[J]. CHEMISTRY & BIOLOGY, 1997, 4 (01): : 51 - 61
[4] Cyclic aristeromycin diphosphate ribose: A potent and poorly hydrolysable Ca2+-mobilising mimic of cyclic adenosine diphosphate ribose
Bailey, VC
Fortt, SM
Summerhill, RJ
Galione, A
Potter, BVL
[J]. FEBS LETTERS, 1996, 379 (03): : 227 - 230
[5] HALOGENATION OF TUBERCIDIN BY N-HALOSUCCINIMIDES - A DIRECT ROUTE TO 5-BROMOTUBERCIDIN, A REVERSIBLE INHIBITOR OF RNA-SYNTHESIS IN EUKARYOTIC CELLS
BERGSTROM, DE
BRATTESANI, AJ
[J]. NUCLEIC ACIDS RESEARCH, 1980, 8 (24) : 6213 - 6219
[6] Briggs AP, 1922, J BIOL CHEM, V53, P13
[7] CLAPPER DL, 1987, J BIOL CHEM, V262, P9561
[8] CA-2+-INDUCED CA-2+ RELEASE AND ITS MODULATION BY CYCLIC ADP-RIBOSE
GALIONE, A
[J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (08) : 304 - 306
[9] GARRETT ER, 1972, J AM CHEM SOC, V94, P8532, DOI 10.1021/ja00779a040
[10] GUSE AH, 1995, J IMMUNOL, V155, P3353

← 1 2 3 →